PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.04%
Revenue growth under 50% of MCHP's 7.70%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
0.29%
Gross profit growth under 50% of MCHP's 9.69%. Michael Burry would be concerned about a severe competitive disadvantage.
0.32%
EBIT growth below 50% of MCHP's 90.11%. Michael Burry would suspect deeper competitive or cost structure issues.
-0.96%
Negative operating income growth while MCHP is at 43.81%. Joel Greenblatt would press for urgent turnaround measures.
297.09%
Net income growth above 1.5x MCHP's 24.60%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
294.29%
EPS growth above 1.5x MCHP's 19.35%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
297.06%
Diluted EPS growth above 1.5x MCHP's 25.00%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.20%
Share reduction while MCHP is at 3.02%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.20%
Reduced diluted shares while MCHP is at 1.56%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.20%
Maintaining or increasing dividends while MCHP cut them. John Neff might see a strong edge in shareholder returns.
-42.35%
Negative OCF growth while MCHP is at 6.95%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-45.64%
Negative FCF growth while MCHP is at 7.77%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
56.33%
10Y revenue/share CAGR under 50% of MCHP's 249.97%. Michael Burry would suspect a lasting competitive disadvantage.
47.90%
5Y revenue/share CAGR under 50% of MCHP's 132.78%. Michael Burry would suspect a significant competitive gap or product weakness.
27.80%
3Y revenue/share CAGR under 50% of MCHP's 60.38%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
134.19%
10Y OCF/share CAGR at 75-90% of MCHP's 167.45%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.
247.85%
5Y OCF/share CAGR above 1.5x MCHP's 125.55%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
94.00%
3Y OCF/share CAGR 1.25-1.5x MCHP's 81.57%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
178.55%
Net income/share CAGR above 1.5x MCHP's 101.97% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
324.95%
5Y net income/share CAGR above 1.5x MCHP's 82.74%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
121.24%
3Y net income/share CAGR above 1.5x MCHP's 65.55%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
45.75%
10Y equity/share CAGR at 75-90% of MCHP's 57.41%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
9.43%
Below 50% of MCHP's 42.59%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
9.04%
Below 50% of MCHP's 37.24%. Michael Burry suspects a serious short-term disadvantage in building book value.
520.16%
10Y dividend/share CAGR above 1.5x MCHP's 28.95%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
196.58%
5Y dividend/share CAGR above 1.5x MCHP's 3.18%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
82.35%
3Y dividend/share CAGR above 1.5x MCHP's 1.59%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
13.77%
AR growth well above MCHP's 10.57%. Michael Burry fears inflated revenue or higher default risk in the near future.
3.83%
Inventory growth well above MCHP's 2.31%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-0.77%
Negative asset growth while MCHP invests at 2.73%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
3.16%
BV/share growth above 1.5x MCHP's 1.28%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
0.02%
Debt shrinking faster vs. MCHP's 1.51%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
-0.26%
Our R&D shrinks while MCHP invests at 2.59%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
5.87%
SG&A growth well above MCHP's 2.80%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.